Oruka Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-105.4M | $-83.7M | $-5.3M | $-9.9M | $-19.3M | $-9.7M | $-5.5M | $-7.9M |
| Depreciation & Amortization | — | — | $15.0K | $20.0K | $16.0K | $8.0K | $18.0K | $22.0K |
| Depreciation | $83.0K | $27.0K | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $24.2M | $14.9M | $686.0K | $556.0K | $497.0K | $43.0K | $151.0K | $273.0K |
| Net Cash from Operating Activities | $-88.2M | $-57.8M | $-5.0M | $-10.9M | $-18.8M | $-7.7M | $-4.8M | $-8.2M |
| Investing Activities | ||||||||
| Capital Expenditures | $209.0K | $189.0K | $0 | $2.0K | $43.0K | $19.0K | $4.0K | $4.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-96.7M | $-330.1M | $0 | $-2.0K | $-43.0K | $-19.0K | $-4.0K | $3.0M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $170.3M | $449.5M | $0 | $0 | $23.1M | $48.5M | $6.6M | $3.1M |
| Net Change in Cash | — | — | $-5.0M | $-10.9M | $4.3M | $40.7M | $1.8M | $-2.1M |
| Free Cash Flow | $-88.4M | $-58.0M | $-5.0M | $-10.9M | $-18.8M | $-7.7M | $-4.8M | $-8.2M |